Fundamental Analysis of Voyager Therapeutics Inc - Growth / Value Index
VYGR - Valuation Highlights
Valuation Analysis
Book Value in last 3 years is trending up
Tsr Value Index - Poor Score of 21.88
Price to Book Ratio of 525.44 suggesting that it is very expensive
Valuation Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Price to Earning | -30469.79 | 7.10 | 201.86 % | |
| Price to Book | 396.57 | 1.57 | -71.33 % | 1.41 |
| Price to Sales | 779.12 | 2.34 | -70.35 % | |
| Enterprise Value to EBITDA Multiple | -32.23 | 5.43 | 191.89 % |
VYGR - Profitability Highlights
Profitability Analysis
Tsr Profitability Index - Excellent Score of 95.00
Piotroski F Score - Excellent Value of 8.0
Net profit has jumped from negative to positive
Company Earning excess return
During the past twelve months, the company has given a strong Return On Equity of 74.55%
During the past twelve months, the company has given a strong Return On Asset of 45.41%
During the past twelve months, the company has given a strong Net Margin of 52.93%
All key Trailing Twelve Months Margin growing by 15 %
Annual Net Profit in last 3 years is trending up
EBITDA is continuously increasing for last 3 Years
Good Return On Capital Employed of 22.13
Very Low Dividend Yield of 0 %
Profitability Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Return On Equity | -1.30 | 22.13 | 128.15 % | -3.32 |
| Return On Asset | -0.861 | 14.89 | 151.13 % | -2.41 |
| Net Profit Margin | -2.56 | 33.02 | 129.11 % | -58.05 |
| Operating Profit Margin | -14.32 | 27.39 | 122.04 % | -82.92 |
| EBITDA Margin | -10.24 | 35.51 | 137.81 % | -76.79 |
Highlights
| Market Cap | 458538 K |
| Enterprise Value | 392936 K |
| Price/Book TTM | 396.57 |
| Outstanding Share | 54393.60 K |
| Float/ Outstanding Share | 67.49% |
| Dividend Yield | 0 % |
Share Holding
Guru Numbers
| Price/Graham No | 0 |
| Peter Lynch Ratio | 0 |
| Piotroski F Score | 8.00 |
| Altman Z Score | 3.16 |
| Sloan Ratio | -0.106 |
| Peter Lynch Fair Value | 0 |
VYGR - Growth Highlights
Growth Analysis
STRONG JUMP IN NET SALE : YoY growth
Growth Key Fields
| Field | TTM | YoY Growth | QoQ Growth |
|---|---|---|---|
| Revenue | 119044 K | 287.21 % | 78.33 % |
| Gross Profit | 90617.00 K | 500.31 % | 108.54 % |
| EBITDA | -12190.00 K | 246.39 % | 125.96 % |
| Net Profit | -3044.00 K | 212.72 % | 120.09 % |
| EPS | -0.0003 | 198.17 % | NA |
VYGR - Stability Highlights
Stability Analysis
Tsr Stability Index - Excellent Score of 91.07
Altman Z Score of 3.18 suggests good Stability
Debt to equity ratio has decreased and is lowest in last three years
Cash ratio of 3.58
Interest Coverage of 0
Stability Key Ratios
| Ratio | Latest FY | Yoy Change | MRQ |
|---|---|---|---|
| Debt to Equity Ratio | 0.0135 | -71.78 % | -0.151 |
| Cash Ratio | 3.58 | 118.60 % | |
| Quick Ratio | 4.96 | 190.77 % | 5.64 |
| Shareholders Equity | 67.27 | 81.64 % | |
| Debt to EBITDA | 0.057 | 177.19 % |
Historical Valuation Ratios of Voyager Therapeutics Inc
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of Voyager Therapeutics Inc
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of Voyager Therapeutics Inc
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of Voyager Therapeutics Inc
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)